Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Insider Joanne Quan Sells 6,969 Shares of Stock

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) insider Joanne Quan sold 6,969 shares of the stock in a transaction that occurred on Friday, January 17th. The stock was sold at an average price of $45.86, for a total value of $319,598.34. Following the completion of the transaction, the insider now owns 5,649 shares in the company, valued at approximately $259,063.14. The trade was a 55.23 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link.

Mirum Pharmaceuticals Trading Up 2.2 %

Shares of MIRM stock opened at $47.98 on Wednesday. The company has a debt-to-equity ratio of 1.33, a quick ratio of 3.15 and a current ratio of 3.34. The company has a market capitalization of $2.30 billion, a price-to-earnings ratio of -23.75 and a beta of 0.98. Mirum Pharmaceuticals, Inc. has a 52-week low of $23.14 and a 52-week high of $48.89. The company has a 50-day simple moving average of $43.48 and a two-hundred day simple moving average of $41.27.

Mirum Pharmaceuticals (NASDAQ:MIRM) last issued its quarterly earnings results on Tuesday, November 12th. The company reported ($0.30) EPS for the quarter, beating analysts’ consensus estimates of ($0.45) by $0.15. Mirum Pharmaceuticals had a negative return on equity of 41.22% and a negative net margin of 31.69%. The company had revenue of $90.38 million during the quarter, compared to the consensus estimate of $81.99 million. During the same period last year, the business posted ($0.57) earnings per share. Mirum Pharmaceuticals’s revenue was up 89.4% on a year-over-year basis. Research analysts anticipate that Mirum Pharmaceuticals, Inc. will post -1.45 EPS for the current fiscal year.

Hedge Funds Weigh In On Mirum Pharmaceuticals

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Amalgamated Bank increased its holdings in Mirum Pharmaceuticals by 60.8% during the second quarter. Amalgamated Bank now owns 1,357 shares of the company’s stock worth $46,000 after buying an additional 513 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. grew its position in shares of Mirum Pharmaceuticals by 22.6% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,725 shares of the company’s stock valued at $67,000 after acquiring an additional 318 shares during the period. Avanza Fonder AB purchased a new stake in shares of Mirum Pharmaceuticals during the 4th quarter worth approximately $189,000. ProShare Advisors LLC purchased a new position in Mirum Pharmaceuticals in the second quarter valued at approximately $213,000. Finally, Y Intercept Hong Kong Ltd purchased a new position in Mirum Pharmaceuticals in the third quarter valued at approximately $215,000.

Wall Street Analysts Forecast Growth

A number of brokerages recently issued reports on MIRM. HC Wainwright reiterated a “buy” rating and issued a $66.00 target price on shares of Mirum Pharmaceuticals in a report on Wednesday, November 13th. Leerink Partners raised their price objective on shares of Mirum Pharmaceuticals from $47.00 to $49.00 and gave the company an “outperform” rating in a research note on Thursday, October 17th. Robert W. Baird boosted their target price on shares of Mirum Pharmaceuticals from $44.00 to $50.00 and gave the stock an “outperform” rating in a research report on Wednesday, November 13th. Finally, Citigroup upped their target price on shares of Mirum Pharmaceuticals from $65.00 to $68.00 and gave the stock a “buy” rating in a report on Wednesday, November 13th. Ten analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Buy” and an average price target of $57.10.

Mirum Pharmaceuticals Company Profile

Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.